IL17A and diabetes mellitus: 2.6. Clinical Data of Leprdb-Type II Diabetic Mice Receiving Weekly 10 μg/mL, 25 μg/mL, or 50 μg/mL of Anti-IL-17A Intraperitoneal Injections 2- and 6-Months Post-Diabetes